较低的25-氧维生素D与非致残性缺血性脑血管事件患者的严重白质过强度和认知功能有关
Zhengsheng Gu1, Xu Sun1, Chenghao Wu1
1Department of Neurology, Changhai Hospital, the First Affiliated Hospital of Naval Medical University, Shanghai, China.
概括
低维生素D水平和白质病变与中风患者的认知障碍有关. 解决维生素D缺乏症可能有助于预防缺血事件后的认知衰退.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 老年学是一门学科.
背景情况:
- 在非致残性缺血性脑血管事件 (NICE) 后的患者中,认知障碍是一个重大问题.
- 血清25-氧维生素D[25(OH) D]水平和白质强度 (WMH) 是影响神经健康的潜在可修改因素.
- 了解它们的相互作用对于开发有针对性的干预措施至关重要.
研究的目的:
- 调查NICE患者血清25(OH) D水平,WMH和认知功能之间的相关性.
- 为了确定血清25(OH) D水平和WMH是否是认知障碍的独立预测因素.
主要方法:
- 一项前性研究涉及160名年龄在40岁及以上的NICE患者.
- 使用蒙特利尔认知评估 (MoCA) 评估认知功能; WMH 通过 Fazekas 评分进行评估.
- 使用了斯皮尔曼相关性,线性回归和二元逻辑回归分析.
主要成果:
- 没有足够的25(OH) D水平的患者表现出较低的MoCA得分和更高的严重WMH患病率.
- 血清25(OH) D度与MoCA评分正相关,与严重WMH负相关.
- 缺乏25OH) D和严重的WMH独立地与认知障碍有关.
结论:
- 血清25(OH) D水平和WMH独立地与NICE患者的认知障碍有关.
- 维护足够的维生素D水平对于在中风后保持认知功能可能很重要.
- 在这个人群中,WMH是认知能力下降的独立风险因素.
更多相关视频
相关概念视频
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
39
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
39
01:30Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212